Related Experiment Videos
A rationale for the prophylactic use of monophosphoryl lipid A in sepsis and septic shock
1Ribi ImmunoChem Research, Inc., Hamilton, MT 59840.
Abstract:
Monophosphoryl lipid A (MLA), a substructure of bacterial lipopolysaccharide (LPS), is being developed as a prophylactic for sepsis and septic shock. In the present study it was shown that MLA induced a rapid accumulation of IFN-gamma in mice that correlated with an in vivo priming of macrophages. Primed macrophages could be induced in vitro to synthesize nitric oxide, a key mediator of macrophage cytotoxicity. Due to its rapid clearance, MLA was not present in circulation at the time when IFN-gamma accumulated, suggesting that MLA could not synergize with IFN-gamma to systemically activate macrophages in vivo. MLA treatment tolerized mice against the IFN-gamma response--ie., treatment of mice with MLA on day 1 blocked LPS from inducing IFN-gamma on days 2-4. The significance of these results in relation to MLA's ability to enhance non-specific resistance and block LPS lethality in animals is discussed.
Insights
Monophosphoryl lipid A (MLA) primes macrophages for nitric oxide synthesis, enhancing immune response. However, MLA tolerizes the immune system against subsequent lipopolysaccharide (LPS) challenges, impacting its prophylactic potential.
Area of Science:
- Immunology
- Pharmacology
Background:
- Monophosphoryl lipid A (MLA), derived from lipopolysaccharide (LPS), is investigated as a sepsis prophylactic.
- Sepsis and septic shock are life-threatening conditions requiring effective preventative strategies.
Purpose of the Study:
- To investigate the in vivo effects of MLA on macrophage activation and immune response.
- To elucidate the mechanisms underlying MLA's potential prophylactic and tolerizing effects.
Main Methods:
- Mice were treated with MLA to assess IFN-gamma accumulation and macrophage priming.
- In vitro studies were conducted to evaluate nitric oxide synthesis in primed macrophages.
- Mice were challenged with LPS after MLA treatment to evaluate immune tolerance.
Main Results:
- MLA induced rapid IFN-gamma accumulation and in vivo macrophage priming in mice.
- Primed macrophages demonstrated in vitro capacity for nitric oxide synthesis.
- MLA treatment led to immune tolerance, blocking LPS-induced IFN-gamma response.
Conclusions:
- MLA activates macrophages and enhances their cytotoxic potential via nitric oxide production.
- Despite initial immune priming, MLA induces tolerance, limiting its synergistic potential with IFN-gamma in vivo.
- Understanding MLA's dual effects is crucial for its development as a sepsis prophylactic.